ArticleScientific reports2020
Field evaluation of a Pan-Lassa rapid diagnostic test during the 2018 Nigerian Lassa fever outbreak.
Open access · goldAbstract readComparative Study
In one paragraph
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.4field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Lassa Virus-A Persistent and Evolving Threat.Microorganisms · 2026Review
- Science-policy translation for Lassa fever control in West Africa: a qualitative synthesis of regional evidence.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Article
- Lessons in the Wake of a Lassa fever case in the Midwest U.S: epidemiology, management and preparedness gaps.BMC infectious diseases · 2026Review
- Development of a broad-lineage Lassa virus rapid diagnostic test informed by the WHO REASSURED framework.Journal of clinical microbiology · 2026Article
- Review
- Development of a Rapid Diagnostic Test to Distinguish between Emerging Viruses That Cause Hemorrhagic Fever.The American journal of tropical medicine and hygiene · 2025Article
- Evaluation of antigen and antibody assays for surveillance of Lassa virus in peri-domestic rodents in southeastern Sierra Leone: a cross-sectional study.The Lancet. Microbe · 2025Article
- Lassa fever: A comprehensive review of virology, clinical management, and global health implications.World journal of virology · 2025Review
- Detection of Immunoglobulin G and/or IgM antibodies specific for Lassa virus among HIV patients in the Northwestern region of Cameroon.Virology journal · 2025Article
- Evaluation of the diagnostic accuracy of the ReLASV Pan-Lassa Antigen Rapid Test for Lassa Fever in Nigeria.PLOS global public health · 2025Article
- Lassa Fever: Critical Review and Prospects for Control.Tropical medicine and infectious disease · 2024Review
- The Perspectives of Healthcare Professionals on the Strategies, Challenges, and Community Responses to Health System Response and Interventions Towards Lassa Fever Infections and Mortality in Sierra Leone.Risk management and healthcare policy · 2024Article
- The Arenaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens.The Journal of infectious diseases · 2023Article
- Lassa Fever Natural History and Clinical Management.Current topics in microbiology and immunology · 2023Article
- Beyond Lassa Fever: Systemic and structural barriers to disease detection and response in Sierra Leone.PLoS neglected tropical diseases · 2022Article
- Angiomotin Counteracts the Negative Regulatory Effect of Host WWOX on Viral PPxY-Mediated Egress.Journal of virology · 2021Article
- Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012-2019.Microorganisms · 2021Article
- Selection and Characterization of Single-Domain Antibodies for Detection of Lassa Nucleoprotein.Antibodies (Basel, Switzerland) · 2020Article
- Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.Scientific reports · 2020Article
- Survival of Lassa Virus in Blood and Tissue Culture Media and in a Small Particle Aerosol.Pathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 12 institutions in 4 countries.
Matthew L BoisenZalgen Labs, LLC, Germantown, MD, USA.
Eghosa UyigueThe African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
John AiyepadaInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Katherine J SiddleThe Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, MA, USA.
Lisa OestereichBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Diana K S NelsonZalgen Labs, LLC, Germantown, MD, USA.
Duane J BushZalgen Labs, LLC, Germantown, MD, USA.
Megan M RowlandZalgen Labs, LLC, Germantown, MD, USA.
Megan L HeinrichZalgen Labs, LLC, Germantown, MD, USA.
Philomena EromonThe African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
Adeyemi T KayodeThe African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
Ikponmwosa OdiaInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Donatus I AdomehInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Ekene B MuoebonamInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Patience AkhilomenInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Grace OkonofuaInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Blessing OsiemiInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Omigie OmoregieInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Michael AirendeInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Jacqueline AgbukorInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Solomon EhikhametalorInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Chris Okafi AireInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Sophie DuraffourBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Meike PahlmannBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Wiebke BöhmBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Kayla G BarnesThe Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, MA, USA.
Samar MehtaThe Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, MA, USA.
Mambu MomohEastern Polytechnic Institute, Kenema, Sierra Leone.
John Demby SandiViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Augustine GobaViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
Onikepe A FolarinThe African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria.
Ephraim Ogbaini-EmovanInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Danny A AsogunInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Ekaete A TobinInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
George O AkpedeInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Sylvanus A OkogbeninInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Peter O OkokhereInstitute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria.
Donald S GrantViral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
John S SchieffelinSections of Infectious Disease, Departments of Pediatrics and Internal Medicine, School of Medicine, Tulane University, New Orleans, LA, USA.
Pardis C SabetiThe Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University, Cambridge, MA, USA.
Stephan GüntherBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
Christian T HappiThe African Center of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede, Osun State, Nigeria. happic@run.edu.ng.
Luis M BrancoZalgen Labs, LLC, Germantown, MD, USA. lbranco@zalgenlabs.com.
Robert F GarryZalgen Labs, LLC, Germantown, MD, USA. rfgarry@tulane.edu.
Irrua Specialist Teaching Hospital · NGZalgen (United States) · USGerman Center for Infection Research · DEHarvard University · USRedeemer's University · NGMinistry of Health and Sanitation · SLTulane University · USUniversity of Sierra Leone · SLAmbrose Alli University · NGBernhard Nocht Institute for Tropical Medicine · DEBroad Institute · USHoward Hughes Medical Institute · US
Funding
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0MTechnology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0MWest African Emerging Infectious Disease Research Center (WA-EIDRC)U01AI151812 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ANDERSEN, KRISTIAN GRAUGAARD, GARRY, ROBERT F · 2020 to 2024
$13.2MStructure-based design of novel Lassa virus glycoproteins for vaccine developmentR01AI132244 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$6.5MAntibody immunotherapeutics for biodefense against Lassa virusR01AI104621 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2013 to 2017
$5.8MPreclinical evaluation of a potent Lassa fever immunotherapeutic antibody cocktailR01AI132223 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2017 to 2021
$5.7MElucidating Genetic Determinants of Resistance to Lassa Hemorrhagic FeverR01AI114855 · NIAID · BROAD INSTITUTE, INC. · PI SABETI, PARDIS CHRISTINE · 2015 to 2019
$3.8MLate-stage development toward commercialization of multilineage point-of-care Lassa fever diagnosticsR44AI115754 · NIAID · ZALGEN LABS, LLC · PI BRANCO, LUIS MANUEL · 2015 to 2016
$1.9MGlycoprotein Immunoassay to Measure Protective Response to Lassa VaccineR43AI138836 · NIAID · ZALGEN LABS, LLC · PI BOISEN, MATTHEW L · 2018 to 2019
$796kNIAID NIH HHS HHSN272201400048CNIAID NIH HHS R01 AI104621NIAID NIH HHS R01 AI114855NIAID NIH HHS R01 AI132223NIAID NIH HHS R01 AI132244NIAID NIH HHS R43 AI138836NIAID NIH HHS R44 AI115754NIAID NIH HHS U01 AI151812NIAID NIH HHS U19 AI135995NIAID NIH HHS U19 AI142790
Abstract
Lassa virus (LASV) is the causative agent of Lassa fever (LF), an often-fatal hemorrhagic disease. LF is endemic in Nigeria, Sierra Leone and other West African countries. Diagnosis of LASV infection is challenged by the genetic diversity of the virus, which is greatest in Nigeria. The ReLASV Pan-Lassa Antigen Rapid Test (Pan-Lassa RDT) is a point-of-care, in vitro diagnostic test that utilizes a mixture of polyclonal antibodies raised against recombinant nucleoproteins of representative strains from the three most prevalent LASV lineages (II, III and IV). We compared the performance of the Pan-LASV RDT to available quantitative PCR (qPCR) assays during the 2018 LF outbreak in Nigeria. For patients with acute LF (RDT positive, IgG/IgM negative) during initial screening, RDT performance was 83.3% sensitivity and 92.8% specificity when compared to composite results of two qPCR assays. 100% of samples that gave Ct values below 22 on both qPCR assays were positive on the Pan-Lassa RDT. There were significantly elevated case fatality rates and elevated liver transaminase levels in subjects whose samples were RDT positive compared to RDT negative.
Indexed as
AdultAntibodies, ViralAntigens, ViralDiagnostic Tests, RoutineDisease OutbreaksFemaleHumansLassa FeverLassa virusMaleMiddle AgedNigeriaPoint-of-Care SystemsRNA, ViralSensitivity and SpecificitySequence Analysis, RNAAntibodies, ViralAntigens, ViralRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.